Key facts
- This page summarizes Danika R. Harrison's Form 4 filing for Soliton, Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2021, 16:07.
Danika R. Harrison - 16 Dec 2021 Form 4 Insider Report for Soliton, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 16 Dec 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Danika R. Harrison
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Danika R. Harrison filed Form 4 for Soliton, Inc. on 17 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SOLY
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -30,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $1.75
- Footnotes
- F1
SOLY
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $14.62
- Footnotes
- F1
SOLY
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $12.94
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.